{"id":"NCT03654274","sponsor":"Myovant Sciences GmbH","briefTitle":"SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain","officialTitle":"SPIRIT EXTENSION: An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-22","primaryCompletion":"2021-12-16","completion":"2023-01-31","firstPosted":"2018-08-31","resultsPosted":"2023-07-20","lastUpdate":"2023-08-08"},"enrollment":802,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Endometriosis"],"interventions":[{"type":"DRUG","name":"Relugolix","otherNames":["TAK-385","MVT-601"]},{"type":"DRUG","name":"Estradiol/norethindrone acetate","otherNames":["E2/NETA","low-dose hormonal add-back"]}],"arms":[{"label":"Relugolix plus E2/NETA","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on endometriosis-associated pain in participants who previously completed a 24-week treatment period in one of the parent studies (MVT-601-3101 or MVT-601-3102).","primaryOutcome":{"measure":"Percentage Of Participants Who Meet The Dysmenorrhea Responder Criteria At Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Relugolix Plus E2/NETA (Group A)","deltaMin":84.8,"sd":null},{"arm":"Relugolix Plus Delayed E2/NETA (Group B)","deltaMin":82.2,"sd":null},{"arm":"Placebo (Group C)","deltaMin":75.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":169,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","Finland","Georgia","Hungary","Italy","New Zealand","Poland","Portugal","Romania","South Africa","Spain","Ukraine"]},"refs":{"pmids":["38906210","38243752"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":277},"commonTop":["Headache","Nasopharyngitis","Vaginal infection","Vulvovaginal mycotic infection","Corona virus infection"]}}